Carlson Caspers Wins Major Patent Case for Teva Pharmaceuticals

Carlson Caspers, a top-ranked intellectual property law firm based in Minneapolis, recently won a significant victory on behalf of its client Teva Pharmaceuticals USA, Inc. In a decision handed down this week, U.S. District Judge Sidney Stein of the U.S. District Court for the Southern District of New York ruled that Teva, the world’s biggest manufacturer of generic drugs, did not infringe any of Purdue Pharma’s valid patents related to the pain medication Oxycontin.

Of the five patents in dispute in Purdue Pharma LP et al. v. Teva Pharmaceuticals USA Inc [SDNY, Nos. 11-02037 and 12-05083], Judge Sidney Stein agreed with Teva’s “clear and convincing evidence” that four of Purdue’s patents lacked “novelty” and/or were “obvious.” The judge further ruled that Teva had not infringed the fifth patent, and that the patent was also invalid for indefiniteness.

The decision helps clear the path for Teva to market a pain-medication that has secured multi-billion dollar sales annually.

The Carlson Caspers team included Mark Schuman, Todd Werner, Jeffer Ali, Sam Lockner, Jennell Bilek, Sarah Stensland, and Alexandra Olson.

The American College of Trial Lawyers, Chambers and Partners, Legal 500, Best Lawyers in America, Super Lawyers and other industry ratings agencies and publications have recognized Carlson Caspers and its individual attorneys for excellence in intellectual property litigation and counseling. The firm has an established reputation for success across a wide range of complex, technology-driven sectors such as wireless, medical devices, life sciences and pharmaceuticals.